Company Performance - Sigma Lithium Corporation (SGML) closed at $14.41, reflecting an -11.16% change from the previous day, which is less than the S&P 500's daily loss of 0.43% [1] - Over the last month, the company's shares increased by 27.62%, outperforming the Basic Materials sector's gain of 7.73% and the S&P 500's loss of 0.5% [1] Earnings Estimates - The upcoming earnings disclosure is expected to show an EPS of -$0.12, a 50% decrease compared to the same quarter last year [2] - The consensus estimate projects revenue of $35.9 million, indicating a 25.26% decline from the equivalent quarter last year [2] Full Year Projections - For the full year, Zacks Consensus Estimates project an EPS of -$0.35 and revenue of $129 million, reflecting changes of +23.91% and -15.18% respectively from the previous year [3] Analyst Estimates and Stock Performance - Recent changes to analyst estimates for Sigma Lithium Corporation are linked to stock price performance, with positive revisions indicating a favorable business outlook [3][4] - Sigma Lithium Corporation currently holds a Zacks Rank of 3 (Hold), with no changes in the Zacks Consensus EPS estimate over the past month [5] Valuation Metrics - The company has a Forward P/E ratio of 25.75, which is a premium compared to the industry average Forward P/E of 23.99 [6] - Sigma Lithium Corporation's PEG ratio stands at 0.43, while the Mining - Miscellaneous industry has an average PEG ratio of 0.7 [7] Industry Ranking - The Mining - Miscellaneous industry, part of the Basic Materials sector, has a Zacks Industry Rank of 47, placing it in the top 20% of over 250 industries [7] - The Zacks Industry Rank measures the strength of industry groups by the average Zacks Rank of individual stocks, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [8]

Company Performance - AZZ closed at $135.98, reflecting a +1.18% change from the previous day, outperforming the S&P 500's loss of 0.43% [1] - Over the past month, AZZ shares have increased by 7.55%, while the Industrial Products sector gained 10.19% and the S&P 500 lost 0.5% [1] Earnings Projections - The upcoming earnings release is projected to show earnings per share (EPS) of $1.19, a 21.43% increase from the same quarter last year [2] - Quarterly revenue is estimated at $383.63 million, representing a 9.02% increase from the previous year [2] Annual Estimates - For the annual period, earnings are anticipated to be $6.04 per share, indicating a +16.15% change from last year, with revenue expected to reach $1.65 billion, up +4.73% [3] Analyst Revisions - Changes in analyst estimates for AZZ are crucial as they reflect the evolving business trends, with positive revisions indicating optimism about the company's outlook [3] Zacks Rank and Valuation - AZZ currently holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate having decreased by 0.11% over the past month [5] - The Forward P/E ratio for AZZ is 22.24, which is lower than the industry average of 27.72, suggesting that AZZ is trading at a discount [6] Industry Context - The Manufacturing - Electronics industry, part of the Industrial Products sector, has a Zacks Industry Rank of 77, placing it in the top 32% of over 250 industries [6] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Company Overview - Ubiquiti Inc. (UI) currently holds a Momentum Style Score of B, indicating a favorable position in momentum investing [3] - The company has a Zacks Rank of 1 (Strong Buy), which is associated with a strong track record of outperformance [4] Price Performance - Over the past week, Ubiquiti's shares have increased by 4.2%, while the Zacks Wireless Equipment industry has decreased by 0.24% [6] - In a longer time frame, Ubiquiti's shares have risen by 34.33% over the past month, outperforming the industry's 10.35% [6] - Over the last quarter, Ubiquiti's shares have increased by 33.84%, and over the past year, they have gained 128.71%, compared to the S&P 500's increases of 1.72% and 17.27%, respectively [7] Trading Volume - Ubiquiti's average 20-day trading volume is 119,008 shares, which serves as a price-to-volume baseline for assessing stock momentum [8] Earnings Outlook - In the past two months, one earnings estimate for Ubiquiti has moved higher, while none have moved lower, resulting in an increase in the consensus estimate from $12.90 to $14.15 [10] - For the next fiscal year, one estimate has also moved upwards with no downward revisions during the same period [10] Conclusion - Given the positive momentum indicators and earnings outlook, Ubiquiti Inc. is positioned as a strong buy candidate for investors seeking short-term opportunities [12]

Core Viewpoint - Investors are evaluating XP Inc.A (XP) and Blackstone Inc. (BX) to determine which stock offers better value opportunities at present [1] Group 1: Zacks Rank and Value Assessment - XP Inc.A has a Zacks Rank of 2 (Buy), indicating a more favorable earnings estimate revision trend compared to Blackstone Inc., which has a Zacks Rank of 3 (Hold) [3] - The Zacks Rank strategy focuses on companies with positive earnings estimate revisions, while the Style Scores system grades companies based on specific traits [2] Group 2: Valuation Metrics - XP has a forward P/E ratio of 11.18, significantly lower than BX's forward P/E of 18.51, suggesting XP may be undervalued [5] - XP's PEG ratio is 0.79, indicating a favorable valuation when considering expected earnings growth, while BX's PEG ratio stands at 1.01 [5] - XP's P/B ratio is 2.78, compared to BX's P/B of 4.25, further supporting the notion that XP is a more attractive value option [6] Group 3: Overall Value Grade - XP has a Value grade of A, while BX has a Value grade of D, highlighting XP's superior valuation metrics and solid earnings outlook [6]

Core Viewpoint - The analysis compares Insteel Industries (IIIN) and Carpenter Technology (CRS) to determine which stock is more attractive to value investors [1] Valuation Metrics - Both IIIN and CRS currently hold a Zacks Rank of 2 (Buy), indicating positive earnings estimate revisions and an improving earnings outlook for both companies [3] - IIIN has a forward P/E ratio of 12.54, while CRS has a significantly higher forward P/E of 38.67 [5] - The PEG ratio for IIIN is 1.04, which is lower than CRS's PEG ratio of 1.56, suggesting that IIIN may be undervalued relative to its expected earnings growth [5] - IIIN's P/B ratio is 2.06, compared to CRS's P/B ratio of 9.97, further indicating that IIIN is a more attractive value option [6] Value Grades - Based on the valuation metrics, IIIN has a Value grade of B, while CRS has a Value grade of F, suggesting that IIIN is the superior value option at this time [6]

Core Viewpoint - Textron's recent earnings report showed mixed results, with adjusted earnings per share slightly missing estimates but revenues exceeding expectations, indicating a strong year-over-year growth trend [2][3]. Financial Performance - Adjusted earnings for Q4 2025 were reported at $1.73 per share, missing the Zacks Consensus Estimate of $1.74 by 0.8%, but reflecting a 29.1% increase from $1.34 in the same quarter last year [2]. - Total revenues for Q4 2025 reached $4.18 billion, surpassing the Zacks Consensus Estimate of $4.14 billion by 0.8%, and showing a 15.7% increase from $3.61 billion in the previous year [3]. Segmental Performance - **Textron Aviation**: Revenues increased by 36% year-over-year to $1.7 billion, driven by higher volumes and a recovery from a strike, with 49 jets delivered compared to 32 a year ago [4]. - **Bell**: Revenues amounted to $1.3 billion, an 11% increase from the previous year, supported by higher volume on the U.S. Army's MV-75 program [5]. - **Textron Systems**: Revenues were $323 million, up $12 million from the prior year, with a backlog of $3.3 billion [6]. - **Industrial**: Revenues declined by $48 million to $821 million due to the divestiture of the Powersports business [6]. - **Finance**: Revenues increased to $18 million from $11 million in the year-ago quarter [7]. Financial Position - As of January 3, 2026, cash and cash equivalents totaled $1.94 billion, up from $1.39 billion a year earlier, with cash generated from operating activities amounting to $1.33 billion compared to $1.01 billion last year [9]. - Long-term debt increased to $3.53 billion from $2.89 billion as of December 28, 2024 [9]. Guidance - For 2026, Textron expects revenues of approximately $15.5 billion and adjusted earnings in the range of $6.40 to $6.60 per share, with the Zacks Consensus Estimate for earnings at $6.67 per share [10]. Market Sentiment - There has been a downward trend in estimates revisions, with the consensus estimate shifting down by 6.07% over the past month [11]. - Textron currently holds a Zacks Rank 3 (Hold), indicating an expectation of in-line returns in the coming months [13]. Industry Context - Textron operates within the Zacks Aerospace - Defense industry, where Northrop Grumman reported revenues of $11.71 billion for the last quarter, reflecting a year-over-year change of +9.6% [14].

Core Viewpoint - CONMED Corporation has shown a positive performance with a 22.9% increase in shares since the last earnings report, outperforming the S&P 500, raising questions about the sustainability of this trend leading up to the next earnings release [1] Financial Performance - Adjusted earnings per share (EPS) for Q4 2025 was $1.43, a 6.7% increase year over year, while GAAP EPS was 54 cents, down 50% from $1.08 in the previous year [2] - Total revenues for Q4 were $373.2 million, reflecting a 7.9% year-over-year increase, and full-year revenues reached $1.37 billion, up 5.2% from the previous year [3] Segment Performance - Orthopedic Surgery revenues in Q4 totaled $157.4 million, up 13.2% year over year, while General Surgery revenues were $215.8 million, up 4.3% [4] - U.S. General Surgery sales declined by 0.4%, but international sales increased by 16.3% [5] Geographical Results - Domestic revenues in Q4 were $206.2 million, up 1.4% year over year, while international revenues were $167 million, up 17% [6] Margin Analysis - Gross profit increased by 10.1% year over year to $218.3 million, with a gross margin of 58.5%, while total operating profit fell by 30.2% to $36.6 million [8][9] Financial Position - Cumulative net cash provided by operating activities at the end of Q4 2025 was $170.7 million, compared to $166.9 million a year ago [10] Guidance - For 2026, total reported revenues are expected to be between $1,345 million and $1,375 million, with adjusted EPS projected in the range of $4.30 to $4.45 [11] Estimate Trends - Since the earnings release, there has been a downward trend in estimates, with a consensus estimate shift of -11.71% [12] VGM Scores - CONMED has an average Growth Score of C, a Momentum Score of D, and a Value Score of A, resulting in an aggregate VGM Score of B [13] Outlook - Estimates for the stock have been trending downward, indicating a potential in-line return in the coming months, with a Zacks Rank of 3 (Hold) [14]

Company Overview - Chewy, Inc. is a pure-play e-commerce company focused on pet products and services, including food, treats, supplies, medications, and broader pet health [11] - The company launched operations in 2011 and became a Delaware corporation in 2016, partnering with approximately 3,200 brands and offering about 130,000 products [11] - Chewy operates the 1 pet pharmacy in America and has developed a technology-enabled ecosystem that includes telehealth services, medication compounding, and insurance offerings under the CarePlus suite [11] Financial Performance - Chewy has a Zacks Rank of 3 (Hold) and a VGM Score of A, indicating a solid position in the market [12] - The company is projected to have year-over-year earnings growth of 23.1% for the current fiscal year, making it a potential top pick for growth investors [12] - One analyst has revised their earnings estimate higher for fiscal 2026, with the Zacks Consensus Estimate increasing by $0.01 to $1.28 per share [12] - Chewy boasts an average earnings surprise of +10.7%, reflecting its ability to exceed earnings expectations [12] Investment Potential - With a solid Zacks Rank and top-tier Growth and VGM Style Scores, Chewy should be considered for investors' short lists [13]

Core Insights - Zacks Premium offers tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1][2] Zacks Style Scores - Zacks Style Scores provide a rating system for stocks based on value, growth, and momentum, helping investors identify securities likely to outperform the market in the short term [2][3] - Stocks are rated from A to F, with A indicating the highest potential for outperformance [3] Value Score - The Value Style Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Sales [3] Growth Score - The Growth Style Score evaluates stocks based on projected earnings, sales, and cash flow to identify those with sustainable growth potential [4] Momentum Score - The Momentum Style Score assesses stocks based on price trends and earnings estimate changes, aiding investors in timing their stock purchases [5] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors seeking attractive value, growth, and momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to help investors build successful portfolios, with 1 (Strong Buy) stocks yielding an average annual return of +23.86% since 1988 [7][9] - There are over 800 stocks rated 1 or 2, making it essential for investors to utilize Style Scores to narrow down their choices [8] Stock Highlight: Merit Medical Systems, Inc. (MMSI) - Merit Medical, headquartered in South Jordan, UT, specializes in peripheral and cardiac intervention products and holds a 2 (Buy) rating on the Zacks Rank with a VGM Score of B [11] - The company is projected to achieve a year-over-year earnings growth of 5% for the current fiscal year, with upward revisions in earnings estimates [12] - MMSI has an average earnings surprise of +13.2%, making it a strong candidate for growth investors [12]

Core Viewpoint - Allurion Technologies, Inc. (ALUR) is being evaluated for its performance relative to its peers in the Medical sector, with a focus on its year-to-date stock performance and earnings outlook [1]. Group 1: Company Performance - Allurion Technologies, Inc. is part of the Medical group, which consists of 925 companies and holds the 8 position in the Zacks Sector Rank [2]. - The Zacks Rank for ALUR is currently 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3]. - Over the past 90 days, the Zacks Consensus Estimate for ALUR's full-year earnings has increased by 73.9%, reflecting improved analyst sentiment [4]. - Year-to-date, ALUR has returned 1.6%, matching the average gain of 1.6% for the Medical group [4]. - In comparison, McKesson (MCK), another Medical stock, has outperformed with an 18.8% increase year-to-date [4]. Group 2: Industry Context - Allurion Technologies, Inc. is categorized under the Medical - Products industry, which includes 82 companies and is currently ranked 139 in the Zacks Industry Rank [5]. - Stocks in the Medical - Products industry have experienced a decline of about 1.5% year-to-date, indicating that ALUR is performing better than its industry peers [5]. - McKesson belongs to the Medical - Dental Supplies industry, which has 15 stocks and is ranked 68, with an industry gain of +7.5% year-to-date [6].